Entresto (Sacubitril/Valsartan) Patent Expiration, LOE Window & CMS Spending
Entresto (Sacubitril/Valsartan) by Novartis: FDA Orange Book core substance LOE 2027-11-27 (last listed 2036-05-09), 16 AB generics, $4.64B 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N207620 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2027-11-27 |
| Last Listed Patent or Exclusivity Date | 2036-05-09 |
| Orange Book Patents (*PED Extensions) | 8 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 16 |
| 2024 CMS Total Public Spend | $4.64B |
| 2024 Medicare Part D Spend | $4.02B |
| 2024 Medicaid Spend | $624.3M |
| Reported Wholesale Price Change (CA SB 17) | 12 WAC filings (max 22.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.